169 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties
8-K
EX-99.1
2grh ozyd
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-99.1
gcwevzoyk3zjtb7dcpf
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
792nf8
31 Jan 24
Other Events
5:07pm
8-K
EX-99.1
zr01ks4kdueuguju668j
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
EX-99.1
xjg8tbjr
6 Dec 23
Other Events
7:13am
8-K
EX-99.1
uj4hcfz1 mu6qxvxe
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
69e uz0yjii5pcvwx
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
focwbca 5ql4z
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.1
hezu9n cz3fvdt3rbn
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
8c4ibt3eatli
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
4fm58dcvtu451w8
30 May 23
Business combination disclosure
4:21pm
8-K
6b7c1a8
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
ujaz7zq
22 May 23
Business combination disclosure
7:01am